|
T3-T4 tabs (Asia pharma)
Generic Name:
synthetic thyroxine/triiodothyronine T4/T3
Description:
Levothyroxine
sodium is used for the following indications:
Hypothyroidism- As replacement or supplemental therapy in congenital or
acquired hypothyroidism of any etiology, except transient hypothyroidism
during the recovery phase of subacute thyroiditis. Specific indications
include: primary (thyroidal), secondary (pituitary), and tertiary
(hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary
hypothyroidism may result from functional deficiency, primary atrophy,
partial or total congenital absence of the thyroid gland, or from the
effects of surgery, radiation, or drugs, with or without the presence of
goiter.
Pituitary TSH Suppression- In the treatment or prevention of various
types of euthyroid goiters (see WARNINGS and PRECAUTIONS), including
thyroid nodules (see WARNINGS and PRECAUTIONS), subacute or chronic
lymphocytic thyroiditis (Hashimoto's thyroiditis), multinodular goiter
(see WARNINGS and PRECAUTIONS) and, as an adjunct to surgery and
radioiodine therapy in the management of thyrotropin-dependent
well-differentiated thyroid cancer.
DOSAGE AND
ADMINISTRATION General Principles
The goal of replacement therapy is to achieve and maintain a clinical
and biochemical euthyroid state. The goal of suppressive therapy is to
inhibit growth and/or function of abnormal thyroid tissue. The dose of
SYNTHROID that is adequate to achieve these goals depends on a variety
of factors including the patient's age, body weight, cardiovascular
status, concomitant medical conditions, including pregnancy, concomitant
medications, and the specific nature of the condition being treated (see
WARNINGS and PRECAUTIONS). Hence, the following recommendations serve
only as dosing guidelines. Dosing must be individualized and adjustments
made based on periodic assessment of the patient's clinical response and
laboratory parameters (see PRECAUTIONS, Laboratory Tests).
SYNTHROID is administered as a single daily dose, preferably one-half to
one-hour before breakfast. SYNTHROID should be taken at least 4 hours
apart from drugs that are known to interfere with its absorption (see
PRECAUTIONS: DRUG INTERACTIONS).
Due to the long half-life of levothyroxine, the peak therapeutic effect
at a given dose of levothyroxine sodium may not be attained for 4-6
weeks.
Caution should be exercised when administering SYNTHROID to patients
with underlying cardiovascular disease, to the elderly, and to those
with concomitant adrenal insufficiency (see PRECAUTIONS). Specific
Patient Populations Hypothyroidism in Adults and in Children in Whom
Growth and Puberty are Complete
(see WARNINGS and PRECAUTIONS, Laboratory Tests)
Therapy may begin at full replacement doses in otherwise healthy
individuals less than 50 years old and in those older than 50 years who
have been recently treated for hyperthyroidism or who have been
hypothyroid for only a short time (such as a few months). The average
full replacement dose of levothyroxine sodium is approximately 1.7
mcg/kg/day (e.g., 100-125 mcg/dayfor a 70 kg adult). Older patients may
require less than 1 mcg/kg/day. Levothyroxine sodium doses greater than
200 mcg/day are seldom required. An inadequate response to daily doses ≥
300 mcg/day is rare and may indicate poor compliance, malabsorption,
and/or drug interactions.
For most patients older than 50 years or for patients under 50 years of
age with underlying cardiac disease, an initial starting dose of 25-50
mcg/dayof levothyroxine sodium is recommended, with gradual increments
in dose at 6-8 week intervals, as needed. The recommended starting dose
of levothyroxine sodium in elderly patients with cardiac disease is
12.5-25 mcg/day, with gradual dose increments at 4-6 week intervals. The
levothyroxine sodium dose is generally adjusted in 12.5-25 mcg
increments until the patient with primary hypothyroidism is clinically
euthyroid and the serum TSH has normalized.
In patients with severe hypothyroidism, the recommended initial
levothyroxine sodium dose is 12.5-25 mcg/daywith increases of 25 mcg/day
every 2-4 weeks, accompanied by clinical and laboratory assessment,
until the TSH level is normalized.
In patients with secondary (pituitary) or tertiary (hypothalamic)
hypothyroidism, the levothyroxine sodium dose should be titrated until
the patient is clinically euthyroid and the serum free- T4 level is
restored to the upper half of the normal range.
Package:
100 tablets,
0.04 mg per tablet.
|
|
